8.91
Telix Pharmaceuticals Ltd Adr stock is traded at $8.91, with a volume of 155.88K.
It is up +1.60% in the last 24 hours and down -18.41% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$8.77
Open:
$8.89
24h Volume:
155.88K
Relative Volume:
0.91
Market Cap:
$3.02B
Revenue:
$417.75M
Net Income/Loss:
$32.27M
P/E Ratio:
91.38
EPS:
0.0975
Net Cash Flow:
-
1W Performance:
-4.60%
1M Performance:
-18.41%
6M Performance:
-46.52%
1Y Performance:
-39.67%
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TLX
Telix Pharmaceuticals Ltd Adr
|
8.91 | 2.94B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX - GlobeNewswire Inc.
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing - Stock Titan
Telix Pharmaceuticals Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsTLX - Stock Titan
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action InvestigationTLX - cnhinews.com
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
TLX Investor News: If You Have Suffered Losses in Telix - GlobeNewswire
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
About Us - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals LimitedTLX - cnhinews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX | Salt Lake City News, Weather, Sports, Breaking News | KUTV - FinancialContent
Telix stock plunges after FDA issues Complete Response Letter - Investing.com
Telix stock plunges after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Telix Shares Drop After FDA Issues Complete Response Letter - MSN
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm - Barchart.com
Telix Pharmaceuticals faces SEC subpoena, investors encouraged to contact Bragar Eagel & Squire. - AInvest
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm - Morningstar
Investigation into Telix Pharmaceuticals Ltd. Allegations of Misleading Business Information - AInvest
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX - Business Wire
Telix Pharmaceuticals under SEC investigation, shareholder lawsuit launched. - AInvest
Regulatory Scrutiny and Biotech Volatility: Lessons from Telix Pharmaceuticals' SEC Subpoena - AInvest
Telix Pharmaceuticals under SEC investigation for securities fraud, shares plummet. - AInvest
Telix Pharmaceuticals Under Investigation for Securities Fraud and Misconduct. - AInvest
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):